Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Sector Analysis

Biological Products, (No Diagnostic Substances)

Standard Industrial Classification: SIC 2836

Industry Insider Sentiment Analysis

The Biological Products, (No Diagnostic Substances) sector (SIC 2836) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.

Filing Date Trade Date Ticker Company Reporting Person Relationship Type Price Qty Total, $ Owned After
2026-11-17 01:33 2026-11-12 HALO HALOZYME THERAPEUTICS, INC. Torley Helen Director, Officer OPT+S $100.01 60,000 $6,000,684 767,780
2026-11-16 21:05 2026-11-12 TWST Twist Bioscience Corp Green Paula Officer SELL $0.00 20,429 $0 126,054
2026-11-16 21:05 2026-11-13 FENC FENNEC PHARMACEUTICALS INC. Brughera Marco Maria Director OPT+S $12.00 20,000 $240,000 0
2026-11-16 20:32 2026-11-12 GILD GILEAD SCIENCES, INC. Kramer Kelly A. Director OPT+S $169.76 10,376 $1,761,437 1,339
2026-11-16 11:43 2026-11-13 AGMB AgomAb Therapeutics NV Epstein David R Director BUY $5.92 14,980 $88,679 54,980
2026-11-13 21:10 2026-11-12 CCCC C4 Therapeutics, Inc. Adams Kendra Officer SELL $2.71 45,173 $122,487 337,150
2026-11-14 00:56 2026-11-11 ADPT Adaptive Biotechnologies Corp BOBULSKY SUSAN Officer SELL $32.00 1,875 $60,000 387,475
2026-11-14 00:59 2026-11-11 ADPT Adaptive Biotechnologies Corp RUBINSTEIN JULIE Officer OPT+S $29.73 35,228 $1,047,304 377,802
2026-11-13 23:00 2026-11-11 RVMD Revolution Medicines, Inc. Anders Jack Officer OPT+S $188.10 35,750 $6,724,689 119,216
2026-11-13 21:32 2026-11-11 EDIT Editas Medicine, Inc. Burkly Linda Officer SELL $2.42 7,814 $18,875 70,379
2026-11-13 21:34 2026-11-11 EDIT Editas Medicine, Inc. O'Neill Gilmore Neil Director, Officer SELL $2.42 21,164 $51,122 265,592
2026-11-13 21:09 2026-11-11 PCVX Vaxcyte, Inc. Dhaliwal Harpreet S. Officer OPT+S $67.83 17,000 $1,153,103 68,085
2026-11-13 13:00 2026-11-11 AIM AIM ImmunoTech Inc. Equels Thomas K Director, Officer BUY $0.15 35,000 $5,215 328,095
2026-11-12 21:11 2026-11-10 DTIL PRECISION BIOSCIENCES INC Scimeca Dario Officer SELL $9.75 2,821 $27,505 56,782
2026-11-13 01:04 2026-11-09 VCEL Vericel Corp Mara Joseph Anthony Jr Officer OPT+S $58.26 25,008 $1,456,979 16,186
2026-11-13 00:43 2026-11-09 VCEL Vericel Corp ZERBE ROBERT L MD Director OPT+S $57.88 2,000 $115,760 32,995
2026-11-13 00:48 2026-11-10 VCEL Vericel Corp MCLAUGHLIN KEVIN F Director OPT+S $58.96 7,000 $412,720 18,300
2026-11-12 23:00 2026-11-09 RVMD Revolution Medicines, Inc. Mancini Anthony Officer OPT+S $200.00 811 $162,200 39,765
2026-11-12 21:41 2026-11-11 IMVT Immunovant, Inc. Pande Atul Director OPT+S $36.00 3,000 $108,000 116,731
2026-11-12 13:00 2026-11-10 AIM AIM ImmunoTech Inc. Equels Thomas K Director, Officer BUY $0.14 39,000 $5,382 293,095
2026-11-11 01:09 2026-11-06 ETRA Electra Therapeutics, Inc. ORBIMED ADVISORS LLC Director, 10% owner BUY $8.08 92,116 $744,528 2,194,579
2026-11-11 01:14 2026-11-06 ETRA Electra Therapeutics, Inc. GORDON CARL L Director, 10% owner BUY $8.08 92,116 $744,528 2,194,579
2026-11-11 00:26 2026-11-09 ADPT Adaptive Biotechnologies Corp RUBINSTEIN JULIE Officer OPT+S $29.82 23,762 $708,557 377,802
2026-11-10 21:30 2026-11-09 REPL Replimune Group, Inc. SLATTERY JOSEPH P Director SELL $21.80 5,200 $113,360 1,467
2026-11-10 15:07 2026-11-09 AIM AIM ImmunoTech Inc. Equels Thomas K Director, Officer BUY $0.16 31,298 $5,070 254,095
2026-11-10 00:20 2026-11-06 GILD GILEAD SCIENCES, INC. Cain Wettan Keeley M Officer SELL $164.11 3,399 $557,810 5,360
2026-11-09 21:05 2026-11-05 VCEL Vericel Corp Mara Joseph Anthony Jr Officer OPT+S $53.48 50,000 $2,674,020 16,186
2026-11-09 20:47 2026-11-06 AIM AIM ImmunoTech Inc. Equels Thomas K Director, Officer BUY $0.16 12,751 $2,015 222,797
2026-11-07 00:24 2026-11-04 ADPT Adaptive Biotechnologies Corp RUBINSTEIN JULIE Officer OPT+S $26.78 35,643 $954,441 377,802
2026-11-06 22:15 2026-11-04 GILD GILEAD SCIENCES, INC. O'Day Daniel Patrick Director, Officer OPT+S $175.16 112,429 $19,693,435 551,683
2026-11-06 21:55 2026-11-04 KOD Kodiak Sciences Inc. BAKER BROS. ADVISORS LP Director, 10% owner BUY $98.51 247,090 $24,340,836 20,424,859
2026-11-06 22:00 2026-11-05 CGEM Cullinan Therapeutics, Inc. Michaelson Jennifer Officer OPT+S $12.36 4,000 $49,440 158,649
2026-11-06 21:05 2026-11-04 VCEL Vericel Corp ZERBE ROBERT L MD Director OPT+S $49.12 5,500 $270,175 32,995
2026-11-06 21:05 2026-11-05 VCEL Vericel Corp Flynn Sean C. Officer OPT+S $51.92 15,000 $778,800 1,990
2026-11-06 21:05 2026-11-05 VCEL Vericel Corp SIEGAL JONATHAN Officer OPT+S $52.90 1,500 $79,350 1,259
2026-11-06 18:58 2026-11-06 AIM AIM ImmunoTech Inc. Equels Thomas K Director, Officer BUY $0.16 20,299 $3,167 210,046
2026-11-06 11:39 2026-11-05 AGMB AgomAb Therapeutics NV Epstein David R Director BUY $6.90 15,000 $103,500 40,000
2026-11-05 21:10 2026-11-03 IPSC Century Therapeutics, Inc. Carr Douglas Officer SELL $1.52 266 $404 502,641
2026-11-06 02:05 2026-11-05 ADMA ADMA BIOLOGICS, INC. Grossman Adam S Director, Officer OPT+S $12.00 147,000 $1,764,000 2,070,777
2026-11-05 22:47 2026-11-03 ETRA Electra Therapeutics, Inc. GORDON CARL L Director, 10% owner BUY $7.63 472,571 $3,605,102 2,136,979
2026-11-05 22:39 2026-11-03 ETRA Electra Therapeutics, Inc. ORBIMED ADVISORS LLC Director, 10% owner BUY $7.63 472,571 $3,605,102 2,136,979
2026-11-05 21:05 2026-11-03 TWST Twist Bioscience Corp Green Paula Officer SELL $135.40 1,007 $136,350 105,625
2026-11-05 21:05 2026-11-03 TWST Twist Bioscience Corp WERNER ROBERT F. Officer SELL $135.40 148 $20,039 42,769
2026-11-05 21:05 2026-11-03 TWST Twist Bioscience Corp Leproust Emily M. Director, Officer SELL $135.40 4,573 $619,193 558,187
2026-11-05 21:05 2026-11-03 TWST Twist Bioscience Corp Finn Patrick John Officer SELL $135.40 2,565 $347,306 180,278
2026-11-05 21:05 2026-11-03 TWST Twist Bioscience Corp Cho Dennis Officer SELL $135.40 949 $128,496 62,840
2026-11-04 21:13 2026-11-02 MAZE Maze Therapeutics, Inc. Coloma Jason V Director, Officer SELL $30.25 34,501 $1,043,766 186,901
2026-11-04 22:12 2026-11-03 RXRX RECURSION PHARMACEUTICALS, INC. Borgeson Blake Director SELL $3.88 40,000 $155,200 6,068,287
2026-11-04 22:12 2026-11-02 LYCA Lycia Therapeutics, Inc. Venrock Healthcare Capital Partners III, L.P. 10% owner BUY $26.95 8,305 $223,820 6,858,542
2026-11-04 21:51 2026-11-02 PCVX Vaxcyte, Inc. Wassil Jim Officer OPT+S $60.90 2,250 $137,024 145,435
SHOW ENTRIES

Sector-Wide Insider Alpha

Analyzing insider movements across the Biological Products, (No Diagnostic Substances) sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2836) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.

SEC Filings in Biological Products, (No Diagnostic Substances)

Every transaction in the Biological Products, (No Diagnostic Substances) industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.